Exact Mass: 344.1736

Exact Mass Matches: 344.1736

Found 129 metabolites which its exact mass value is equals to given mass value 344.1736, within given mass tolerance error 0.01 dalton. Try search metabolite list with more accurate mass tolerance error 0.001 dalton.

Formoterol

3-formylamino-4-Hydroxy-alpha-(N-1-methyl-2-P-methoxyphenethylaminomethyl)benzyl alcohol.hemifumarate

C19H24N2O4 (344.1736)


Formoterol is a long-acting (12 hours) beta2-agonist used in the management of asthma and/or chronic obstructive pulmonary disease (COPD). Inhaled formoterol works like other beta2-agonists, causing bronchodilatation through relaxation of the smooth muscle in the airway so as to treat the exacerbation of asthma. R - Respiratory system > R03 - Drugs for obstructive airway diseases > R03C - Adrenergics for systemic use > R03CC - Selective beta-2-adrenoreceptor agonists R - Respiratory system > R03 - Drugs for obstructive airway diseases > R03A - Adrenergics, inhalants > R03AC - Selective beta-2-adrenoreceptor agonists D019141 - Respiratory System Agents > D018927 - Anti-Asthmatic Agents > D001993 - Bronchodilator Agents C78272 - Agent Affecting Nervous System > C29747 - Adrenergic Agent > C87053 - Adrenergic Agonist D018377 - Neurotransmitter Agents > D018663 - Adrenergic Agents > D000322 - Adrenergic Agonists COVID info from clinicaltrial, clinicaltrials, clinical trial, clinical trials D018373 - Peripheral Nervous System Agents > D001337 - Autonomic Agents Corona-virus Coronavirus SARS-CoV-2 COVID-19 SARS-CoV COVID19 SARS2 SARS

   

alpha,alpha-Diethyl-4,4-bis(2-propynyloxy)stilbene

alpha,alpha-Diethyl-4,4-bis(2-propynyloxy)stilbene

C24H24O2 (344.1776)


   

Arformoterol

3-formylamino-4-Hydroxy-alpha-(N-1-methyl-2-P-methoxyphenethylaminomethyl)benzyl alcohol.hemifumarate

C19H24N2O4 (344.1736)


Arformoterol is a bronchodilator. It works by relaxing muscles in the airways to improve breathing. Arformoterol inhalation is used to prevent bronchoconstriction in people with chronic obstructive pulmonary disease, including chronic bronchitis and emphysema. The use of arformoterol is pending revision due to safety concerns in regards to an increased risk of severe exacerbation of asthma symptoms, leading to hospitalization as well as death in some patients using long acting beta agonists for the treatment of asthma. R - Respiratory system > R03 - Drugs for obstructive airway diseases > R03C - Adrenergics for systemic use > R03CC - Selective beta-2-adrenoreceptor agonists R - Respiratory system > R03 - Drugs for obstructive airway diseases > R03A - Adrenergics, inhalants > R03AC - Selective beta-2-adrenoreceptor agonists D019141 - Respiratory System Agents > D018927 - Anti-Asthmatic Agents > D001993 - Bronchodilator Agents C78272 - Agent Affecting Nervous System > C29747 - Adrenergic Agent > C87053 - Adrenergic Agonist D018377 - Neurotransmitter Agents > D018663 - Adrenergic Agents > D000322 - Adrenergic Agonists D018373 - Peripheral Nervous System Agents > D001337 - Autonomic Agents COVID info from clinicaltrials, clinicaltrial Corona-virus Coronavirus SARS-CoV-2 COVID-19 SARS-CoV COVID19 SARS2 SARS

   

Tamoxifen-ol

2-[4-(1,2-diphenylbut-1-en-1-yl)phenoxy]ethan-1-ol

C24H24O2 (344.1776)


   
   

14beta-Hydroxygelsedine

14beta-Hydroxygelsedine

C19H24N2O4 (344.1736)


   

Dihydrohumantenidine

Dihydrohumantenidine

C19H24N2O4 (344.1736)


   

Hydroxygelsemicine

Hydroxygelsemicine

C19H24N2O4 (344.1736)


   

Acetamide, N,N-[[(2S,5S)-3,6-dioxo-2,5-piperazinediyl]di-3,1-propanediyl]bis[N-hydroxy-

Acetamide, N,N-[[(2S,5S)-3,6-dioxo-2,5-piperazinediyl]di-3,1-propanediyl]bis[N-hydroxy-

C14H24N4O6 (344.1696)


   

3,5,5-trimethyl-4-(2-beta-D-glucopyranosyloxy)ethyl-cyclohexa-2-en-1-one

3,5,5-trimethyl-4-(2-beta-D-glucopyranosyloxy)ethyl-cyclohexa-2-en-1-one

C17H28O7 (344.1835)


   

cytospolide N

cytospolide N

C17H28O7 (344.1835)


   
   
   
   
   

Rhodotulic acid

Rhodotulic acid

C14H24N4O6 (344.1696)


   

formoterol

N-[2-Hydroxy-5-[1-hydroxy-2-[1-(4-methoxyphenyl)propan-2-ylamino]ethyl]phenyl]formamide

C19H24N2O4 (344.1736)


R - Respiratory system > R03 - Drugs for obstructive airway diseases > R03C - Adrenergics for systemic use > R03CC - Selective beta-2-adrenoreceptor agonists R - Respiratory system > R03 - Drugs for obstructive airway diseases > R03A - Adrenergics, inhalants > R03AC - Selective beta-2-adrenoreceptor agonists D019141 - Respiratory System Agents > D018927 - Anti-Asthmatic Agents > D001993 - Bronchodilator Agents C78272 - Agent Affecting Nervous System > C29747 - Adrenergic Agent > C87053 - Adrenergic Agonist D018377 - Neurotransmitter Agents > D018663 - Adrenergic Agents > D000322 - Adrenergic Agonists COVID info from clinicaltrial, clinicaltrials, clinical trial, clinical trials D018373 - Peripheral Nervous System Agents > D001337 - Autonomic Agents Corona-virus Coronavirus SARS-CoV-2 COVID-19 SARS-CoV COVID19 SARS2 SARS

   

Rhodotorulic acid

N-[3-[(2S,5S)-5-[3-[acetyl(hydroxy)amino]propyl]-3,6-dioxopiperazin-2-yl]propyl]-N-hydroxyacetamide

C14H24N4O6 (344.1696)


A member of the class of 2,5-diketopiperazines obtained by cyclodimerisation of N(5)-acetyl-N(5)-hydroxy-L-ornithine. Rhodotorulic acid is a member of the class of 2,5-diketopiperazines obtained by cyclodimerisation of N(5)-acetyl-N(5)-hydroxy-L-ornithine. It has a role as a siderophore and a fungal metabolite. It is a member of 2,5-diketopiperazines, a hydroxamic acid and a L-ornithine derivative. Rhodotorulic acid. CAS Common Chemistry. CAS, a division of the American Chemical Society, n.d. https://commonchemistry.cas.org/detail?cas_rn=18928-00-2 (retrieved 2024-12-11) (CAS RN: 18928-00-2). Licensed under the Attribution-Noncommercial 4.0 International License (CC BY-NC 4.0).

   

Ala Ala Pro Ser

(2S)-2-{[(2S)-1-[(2S)-2-[(2S)-2-aminopropanamido]propanoyl]pyrrolidin-2-yl]formamido}-3-hydroxypropanoic acid

C14H24N4O6 (344.1696)


   

Ala Ala Ser Pro

(2S)-1-[(2S)-2-[(2S)-2-[(2S)-2-aminopropanamido]propanamido]-3-hydroxypropanoyl]pyrrolidine-2-carboxylic acid

C14H24N4O6 (344.1696)


   

Ala Gly Pro Thr

(2S,3R)-2-{[(2S)-1-{2-[(2S)-2-aminopropanamido]acetyl}pyrrolidin-2-yl]formamido}-3-hydroxybutanoic acid

C14H24N4O6 (344.1696)


   

Ala Gly Thr Pro

(2S)-1-[(2S,3R)-2-{2-[(2S)-2-aminopropanamido]acetamido}-3-hydroxybutanoyl]pyrrolidine-2-carboxylic acid

C14H24N4O6 (344.1696)


   

Ala Pro Ala Ser

(2S)-2-[(2S)-2-{[(2S)-1-[(2S)-2-aminopropanoyl]pyrrolidin-2-yl]formamido}propanamido]-3-hydroxypropanoic acid

C14H24N4O6 (344.1696)


   

Ala Pro Gly Thr

(2S,3R)-2-(2-{[(2S)-1-[(2S)-2-aminopropanoyl]pyrrolidin-2-yl]formamido}acetamido)-3-hydroxybutanoic acid

C14H24N4O6 (344.1696)


   

Ala Pro Ser Ala

(2S)-2-[(2S)-2-{[(2S)-1-[(2S)-2-aminopropanoyl]pyrrolidin-2-yl]formamido}-3-hydroxypropanamido]propanoic acid

C14H24N4O6 (344.1696)


   

Ala Pro Thr Gly

2-[(2S,3R)-2-{[(2S)-1-[(2S)-2-aminopropanoyl]pyrrolidin-2-yl]formamido}-3-hydroxybutanamido]acetic acid

C14H24N4O6 (344.1696)


   

Ala Ser Ala Pro

(2S)-1-[(2S)-2-[(2S)-2-[(2S)-2-aminopropanamido]-3-hydroxypropanamido]propanoyl]pyrrolidine-2-carboxylic acid

C14H24N4O6 (344.1696)


   

Ala Ser Pro Ala

(2S)-2-{[(2S)-1-[(2S)-2-[(2S)-2-aminopropanamido]-3-hydroxypropanoyl]pyrrolidin-2-yl]formamido}propanoic acid

C14H24N4O6 (344.1696)


   

Ala Thr Gly Pro

(2S)-1-{2-[(2S,3R)-2-[(2S)-2-aminopropanamido]-3-hydroxybutanamido]acetyl}pyrrolidine-2-carboxylic acid

C14H24N4O6 (344.1696)


   

Ala Thr Pro Gly

2-{[(2S)-1-[(2S,3R)-2-[(2S)-2-aminopropanamido]-3-hydroxybutanoyl]pyrrolidin-2-yl]formamido}acetic acid

C14H24N4O6 (344.1696)


   

Gly Ala Pro Thr

(2S,3R)-2-{[(2S)-1-[(2S)-2-(2-aminoacetamido)propanoyl]pyrrolidin-2-yl]formamido}-3-hydroxybutanoic acid

C14H24N4O6 (344.1696)


   

Gly Ala Thr Pro

(2S)-1-[(2S,3R)-2-[(2S)-2-(2-aminoacetamido)propanamido]-3-hydroxybutanoyl]pyrrolidine-2-carboxylic acid

C14H24N4O6 (344.1696)


   

Gly Pro Ala Thr

(2S,3R)-2-[(2S)-2-{[(2S)-1-(2-aminoacetyl)pyrrolidin-2-yl]formamido}propanamido]-3-hydroxybutanoic acid

C14H24N4O6 (344.1696)


   

Gly Pro Thr Ala

(2S)-2-[(2S,3R)-2-{[(2S)-1-(2-aminoacetyl)pyrrolidin-2-yl]formamido}-3-hydroxybutanamido]propanoic acid

C14H24N4O6 (344.1696)


   

Gly Thr Ala Pro

(2S)-1-[(2S)-2-[(2S,3R)-2-(2-aminoacetamido)-3-hydroxybutanamido]propanoyl]pyrrolidine-2-carboxylic acid

C14H24N4O6 (344.1696)


   

Gly Thr Pro Ala

(2S)-2-{[(2S)-1-[(2S,3R)-2-(2-aminoacetamido)-3-hydroxybutanoyl]pyrrolidin-2-yl]formamido}propanoic acid

C14H24N4O6 (344.1696)


   

Pro Ala Ala Ser

(2S)-3-hydroxy-2-[(2S)-2-[(2S)-2-[(2S)-pyrrolidin-2-ylformamido]propanamido]propanamido]propanoic acid

C14H24N4O6 (344.1696)


   

Pro Ala Gly Thr

(2S,3R)-3-hydroxy-2-{2-[(2S)-2-[(2S)-pyrrolidin-2-ylformamido]propanamido]acetamido}butanoic acid

C14H24N4O6 (344.1696)


   

Pro Ala Ser Ala

(2S)-2-[(2S)-3-hydroxy-2-[(2S)-2-[(2S)-pyrrolidin-2-ylformamido]propanamido]propanamido]propanoic acid

C14H24N4O6 (344.1696)


   

Pro Ala Thr Gly

2-[(2S,3R)-3-hydroxy-2-[(2S)-2-[(2S)-pyrrolidin-2-ylformamido]propanamido]butanamido]acetic acid

C14H24N4O6 (344.1696)


   

Pro Gly Ala Thr

(2S,3R)-3-hydroxy-2-[(2S)-2-{2-[(2S)-pyrrolidin-2-ylformamido]acetamido}propanamido]butanoic acid

C14H24N4O6 (344.1696)


   

Pro Gly Thr Ala

(2S)-2-[(2S,3R)-3-hydroxy-2-{2-[(2S)-pyrrolidin-2-ylformamido]acetamido}butanamido]propanoic acid

C14H24N4O6 (344.1696)


   

Pro Ser Ala Ala

(2S)-2-[(2S)-2-[(2S)-3-hydroxy-2-[(2S)-pyrrolidin-2-ylformamido]propanamido]propanamido]propanoic acid

C14H24N4O6 (344.1696)


   

Pro Thr Ala Gly

2-[(2S)-2-[(2S,3R)-3-hydroxy-2-[(2S)-pyrrolidin-2-ylformamido]butanamido]propanamido]acetic acid

C14H24N4O6 (344.1696)


   

Pro Thr Gly Ala

(2S)-2-{2-[(2S,3R)-3-hydroxy-2-[(2S)-pyrrolidin-2-ylformamido]butanamido]acetamido}propanoic acid

C14H24N4O6 (344.1696)


   
   

Ser Ala Ala Pro

(2S)-1-[(2S)-2-[(2S)-2-[(2S)-2-amino-3-hydroxypropanamido]propanamido]propanoyl]pyrrolidine-2-carboxylic acid

C14H24N4O6 (344.1696)


   

Ser Ala Pro Ala

(2S)-2-{[(2S)-1-[(2S)-2-[(2S)-2-amino-3-hydroxypropanamido]propanoyl]pyrrolidin-2-yl]formamido}propanoic acid

C14H24N4O6 (344.1696)


   

Ser Pro Ala Ala

(2S)-2-[(2S)-2-{[(2S)-1-[(2S)-2-amino-3-hydroxypropanoyl]pyrrolidin-2-yl]formamido}propanamido]propanoic acid

C14H24N4O6 (344.1696)


   
   

Thr Ala Gly Pro

(2S)-1-{2-[(2S)-2-[(2S,3R)-2-amino-3-hydroxybutanamido]propanamido]acetyl}pyrrolidine-2-carboxylic acid

C14H24N4O6 (344.1696)


   

Thr Ala Pro Gly

2-{[(2S)-1-[(2S)-2-[(2S,3R)-2-amino-3-hydroxybutanamido]propanoyl]pyrrolidin-2-yl]formamido}acetic acid

C14H24N4O6 (344.1696)


   

Thr Gly Ala Pro

(2S)-1-[(2S)-2-{2-[(2S,3R)-2-amino-3-hydroxybutanamido]acetamido}propanoyl]pyrrolidine-2-carboxylic acid

C14H24N4O6 (344.1696)


   

Thr Gly Pro Ala

(2S)-2-{[(2S)-1-{2-[(2S,3R)-2-amino-3-hydroxybutanamido]acetyl}pyrrolidin-2-yl]formamido}propanoic acid

C14H24N4O6 (344.1696)


   

Thr Pro Ala Gly

2-[(2S)-2-{[(2S)-1-[(2S,3R)-2-amino-3-hydroxybutanoyl]pyrrolidin-2-yl]formamido}propanamido]acetic acid

C14H24N4O6 (344.1696)


   

Thr Pro Gly Ala

(2S)-2-(2-{[(2S)-1-[(2S,3R)-2-amino-3-hydroxybutanoyl]pyrrolidin-2-yl]formamido}acetamido)propanoic acid

C14H24N4O6 (344.1696)


   

6,9,12,15,18,21-Tetracosahexaynoic acid

6,9,12,15,18,21-Tetracosahexaynoic acid

C24H24O2 (344.1776)


   

Arformoterol

N-{2-hydroxy-5-[(1R)-1-hydroxy-2-{[(2R)-1-(4-methoxyphenyl)propan-2-yl]amino}ethyl]phenyl}formamide

C19H24N2O4 (344.1736)


R - Respiratory system > R03 - Drugs for obstructive airway diseases > R03C - Adrenergics for systemic use > R03CC - Selective beta-2-adrenoreceptor agonists R - Respiratory system > R03 - Drugs for obstructive airway diseases > R03A - Adrenergics, inhalants > R03AC - Selective beta-2-adrenoreceptor agonists D019141 - Respiratory System Agents > D018927 - Anti-Asthmatic Agents > D001993 - Bronchodilator Agents C78272 - Agent Affecting Nervous System > C29747 - Adrenergic Agent > C87053 - Adrenergic Agonist D018377 - Neurotransmitter Agents > D018663 - Adrenergic Agents > D000322 - Adrenergic Agonists D018373 - Peripheral Nervous System Agents > D001337 - Autonomic Agents COVID info from clinicaltrials, clinicaltrial Corona-virus Coronavirus SARS-CoV-2 COVID-19 SARS-CoV COVID19 SARS2 SARS

   

FA 24:12

6,9,12,15,18,21-Tetracosahexaynoic acid

C24H24O2 (344.1776)


   

JNJ-40411813

2(1H)-Pyridinone, 1-butyl-3-chloro-4-(4-phenyl-1-piperidinyl)-

C20H25ClN2O (344.1655)


JNJ-40411813 (ADX-71149) is a novel positive allosteric modulator of the metabotropic Glutamate 2 receptor (mGlu2R) with EC50 of 147 nM. JNJ-40411813 has orally bioactivity and penetrate the blood-brain barriers. JNJ-40411813 has the potential property of anti-depression[1][2][3].

   

1-BOC-3-(4-TRIFLUOROMETHYL-PHENYLAMINO)-PIPERIDINE

1-BOC-3-(4-TRIFLUOROMETHYL-PHENYLAMINO)-PIPERIDINE

C17H23F3N2O2 (344.1712)


   

1-BOC-3-(3-TRIFLUOROMETHYL-PHENYLAMINO)-PIPERIDINE

1-BOC-3-(3-TRIFLUOROMETHYL-PHENYLAMINO)-PIPERIDINE

C17H23F3N2O2 (344.1712)


   
   
   

4-[1-hydroxy-2-[4-(2-methoxyphenyl)piperazin-1-yl]ethyl]benzene-1,2-diol

4-[1-hydroxy-2-[4-(2-methoxyphenyl)piperazin-1-yl]ethyl]benzene-1,2-diol

C19H24N2O4 (344.1736)


   

[(2R,3R,4R)-3-acetyloxy-2-[[tert-butyl(dimethyl)silyl]oxymethyl]-3,4-dihydro-2H-pyran-4-yl] acetate

[(2R,3R,4R)-3-acetyloxy-2-[[tert-butyl(dimethyl)silyl]oxymethyl]-3,4-dihydro-2H-pyran-4-yl] acetate

C16H28O6Si (344.1655)


   

1-BOC-3-([(2-TRIFLUOROMETHYL-PHENYL)-AMINO]-METHYL)-PYRROLIDINE

1-BOC-3-([(2-TRIFLUOROMETHYL-PHENYL)-AMINO]-METHYL)-PYRROLIDINE

C17H23F3N2O2 (344.1712)


   

1-BOC-3-([(3-TRIFLUOROMETHYL-PHENYL)-AMINO]-METHYL)-PYRROLIDINE

1-BOC-3-([(3-TRIFLUOROMETHYL-PHENYL)-AMINO]-METHYL)-PYRROLIDINE

C17H23F3N2O2 (344.1712)


   

1-BOC-3-([(4-TRIFLUOROMETHYL-PHENYL)-AMINO]-METHYL)-PYRROLIDINE

1-BOC-3-([(4-TRIFLUOROMETHYL-PHENYL)-AMINO]-METHYL)-PYRROLIDINE

C17H23F3N2O2 (344.1712)


   

tert-butyl 4-[4-(trifluoromethyl)anilino]piperidine-1-carboxylate

tert-butyl 4-[4-(trifluoromethyl)anilino]piperidine-1-carboxylate

C17H23F3N2O2 (344.1712)


   

tolamolol

tolamolol

C19H24N2O4 (344.1736)


C78272 - Agent Affecting Nervous System > C29747 - Adrenergic Agent > C72900 - Adrenergic Antagonist

   

3,4-DI-O-ACETYL-6-O-(TERT-BUTYLDIMETHYLSILYL)-D-GLUCAL

3,4-DI-O-ACETYL-6-O-(TERT-BUTYLDIMETHYLSILYL)-D-GLUCAL

C16H28O6Si (344.1655)


   

(4,6-DIMETHOXY-PYRIMIDIN-2-YL)-PHENYL-AMINE

(4,6-DIMETHOXY-PYRIMIDIN-2-YL)-PHENYL-AMINE

C21H20N4O (344.1637)


   

1-{2-[(TERT-BUTOXYCARBONYL)AMINO]ETHYL}-2-METHYL-5-PHENYL-1H-PYRROLE-3-CARBOXYLIC ACID

1-{2-[(TERT-BUTOXYCARBONYL)AMINO]ETHYL}-2-METHYL-5-PHENYL-1H-PYRROLE-3-CARBOXYLIC ACID

C19H24N2O4 (344.1736)


   

Bis(hexamethyldisilazido)magnesium,Mg(HMDS)2

Bis(hexamethyldisilazido)magnesium,Mg(HMDS)2

C12H36MgN2Si4 (344.1806)


   

1H-PYRIDO[3,4-B]INDOLE-1-ACETIC ACID, 2-[(1,1-DIMETHYLETHOXY)CARBONYL]-2,3,4,9-TETRAHYDRO-, METHYL ESTER

1H-PYRIDO[3,4-B]INDOLE-1-ACETIC ACID, 2-[(1,1-DIMETHYLETHOXY)CARBONYL]-2,3,4,9-TETRAHYDRO-, METHYL ESTER

C19H24N2O4 (344.1736)


   

SDZ SER 082 fumarate

SDZ SER 082 fumarate

C19H24N2O4 (344.1736)


   

Phenylethanolamine A

Phenylethanolamine A

C19H24N2O4 (344.1736)


   

Ac-Ala-Ala-Ala-Ala-OH

Ac-Ala-Ala-Ala-Ala-OH

C14H24N4O6 (344.1696)


   

Indecainide hydrochloride

Indecainide hydrochloride

C20H25ClN2O (344.1655)


C78274 - Agent Affecting Cardiovascular System > C47793 - Antiarrhythmic Agent

   

Mivavotinib

Mivavotinib

C17H21FN6O (344.1761)


C274 - Antineoplastic Agent > C2189 - Signal Transduction Inhibitor > C129824 - Antineoplastic Protein Inhibitor C471 - Enzyme Inhibitor > C1404 - Protein Kinase Inhibitor > C1967 - Tyrosine Kinase Inhibitor C471 - Enzyme Inhibitor > C129825 - Antineoplastic Enzyme Inhibitor

   

(S,S)-Formoterol

N-[2-Hydroxy-5-[1-hydroxy-2-[1-(4-methoxyphenyl)propan-2-ylamino]ethyl]phenyl]formamide

C19H24N2O4 (344.1736)


R - Respiratory system > R03 - Drugs for obstructive airway diseases > R03C - Adrenergics for systemic use > R03CC - Selective beta-2-adrenoreceptor agonists R - Respiratory system > R03 - Drugs for obstructive airway diseases > R03A - Adrenergics, inhalants > R03AC - Selective beta-2-adrenoreceptor agonists D019141 - Respiratory System Agents > D018927 - Anti-Asthmatic Agents > D001993 - Bronchodilator Agents D018377 - Neurotransmitter Agents > D018663 - Adrenergic Agents > D000322 - Adrenergic Agonists D018373 - Peripheral Nervous System Agents > D001337 - Autonomic Agents COVID info from clinicaltrials, clinicaltrial Corona-virus Coronavirus SARS-CoV-2 COVID-19 SARS-CoV COVID19 SARS2 SARS

   

4-(2-Chloro-10h-Phenoxazin-10-Yl)-N,N-Diethylbutan-1-Amine

4-(2-Chloro-10h-Phenoxazin-10-Yl)-N,N-Diethylbutan-1-Amine

C20H25ClN2O (344.1655)


   

Monic acid A

Monic acid A

C17H28O7 (344.1835)


   

1-[[4-(2-Pyridinyl)-1-piperazinyl]methyl]-2-benzo[cd]indolone

1-[[4-(2-Pyridinyl)-1-piperazinyl]methyl]-2-benzo[cd]indolone

C21H20N4O (344.1637)


   

(2R)-1-[(5,6-Diphenyl-7H-pyrrolo[2,3-D]pyrimidin-4-YL)amino]propan-2-OL

(2R)-1-[(5,6-Diphenyl-7H-pyrrolo[2,3-D]pyrimidin-4-YL)amino]propan-2-OL

C21H20N4O (344.1637)


   

4-({[4-(3-Methylbenzoyl)pyridin-2-Yl]amino}methyl)benzenecarboximidamide

4-({[4-(3-Methylbenzoyl)pyridin-2-Yl]amino}methyl)benzenecarboximidamide

C21H20N4O (344.1637)


   

L-Lys-3-[[(E)-4-Methoxy-4-oxo-2-butenoyl]amino]-L-Ala-OH

L-Lys-3-[[(E)-4-Methoxy-4-oxo-2-butenoyl]amino]-L-Ala-OH

C14H24N4O6 (344.1696)


   

(E)-4-[(2S,3R,4R,5S)-3,4-dihydroxy-5-[[3-[(2S,3S)-3-hydroxybutan-2-yl]oxiran-2-yl]methyl]oxan-2-yl]-3-methylbut-2-enoic acid

(E)-4-[(2S,3R,4R,5S)-3,4-dihydroxy-5-[[3-[(2S,3S)-3-hydroxybutan-2-yl]oxiran-2-yl]methyl]oxan-2-yl]-3-methylbut-2-enoic acid

C17H28O7 (344.1835)


   

2-[4-[(E)-1,2-diphenylbut-1-enyl]phenoxy]ethanol

2-[4-[(E)-1,2-diphenylbut-1-enyl]phenoxy]ethanol

C24H24O2 (344.1776)


   

4-(1-azepanyl)-6-hydrazinyl-N-(4-nitrophenyl)-1,3,5-triazin-2-amine

4-(1-azepanyl)-6-hydrazinyl-N-(4-nitrophenyl)-1,3,5-triazin-2-amine

C15H20N8O2 (344.1709)


   

1-[1-(4-Butan-2-ylphenyl)ethyl]-3-[(4-fluorophenyl)methyl]thiourea

1-[1-(4-Butan-2-ylphenyl)ethyl]-3-[(4-fluorophenyl)methyl]thiourea

C20H25FN2S (344.1722)


   

1-[(4-Fluorophenyl)methyl]-3-[1-(4-propan-2-ylphenyl)propyl]thiourea

1-[(4-Fluorophenyl)methyl]-3-[1-(4-propan-2-ylphenyl)propyl]thiourea

C20H25FN2S (344.1722)


   

4-(3-Methyl-1-phenylpyrazolo[3,4-b]quinolin-4-yl)morpholine

4-(3-Methyl-1-phenylpyrazolo[3,4-b]quinolin-4-yl)morpholine

C21H20N4O (344.1637)


   
   

1-[4-[(4-Ethyl-1-piperazinyl)methyl]phenyl]-3-thiophen-2-ylurea

1-[4-[(4-Ethyl-1-piperazinyl)methyl]phenyl]-3-thiophen-2-ylurea

C18H24N4OS (344.1671)


   
   

2-Hydroxy-5-[1-hydroxy-2-[4-(4-hydroxyphenyl)butan-2-ylamino]ethyl]benzamide

2-Hydroxy-5-[1-hydroxy-2-[4-(4-hydroxyphenyl)butan-2-ylamino]ethyl]benzamide

C19H24N2O4 (344.1736)


   

6-De(cyclopropylamino)-6-(3-cyclopropyl-3-fluoroazetidin-1-yl)abacavir

6-De(cyclopropylamino)-6-(3-cyclopropyl-3-fluoroazetidin-1-yl)abacavir

C17H21FN6O (344.1761)


   
   
   
   
   

2,3-Dihydroxy-5-[1-hydroxy-2-(4-phenylbutan-2-ylamino)ethyl]benzamide

2,3-Dihydroxy-5-[1-hydroxy-2-(4-phenylbutan-2-ylamino)ethyl]benzamide

C19H24N2O4 (344.1736)


   

4-Ethoxycarbonyl-6-ethyl-5-methyl-2-(para-tolyl)perhydropyrrolo(3,4-C)pyrrole-1,3-dione (3A,4-trans-6,6A-cis)

4-Ethoxycarbonyl-6-ethyl-5-methyl-2-(para-tolyl)perhydropyrrolo(3,4-C)pyrrole-1,3-dione (3A,4-trans-6,6A-cis)

C19H24N2O4 (344.1736)


   

4-Ethoxycarbonyl-6-ethyl-5-methyl-2-(para-tolyl)perhydropyrrolo(3,4-C)pyrrole-1,3-dione (3A,4-cis-6,6A-trans)

4-Ethoxycarbonyl-6-ethyl-5-methyl-2-(para-tolyl)perhydropyrrolo(3,4-C)pyrrole-1,3-dione (3A,4-cis-6,6A-trans)

C19H24N2O4 (344.1736)


   

GK921

GK921

C21H20N4O (344.1637)


GK921 is a transglutaminase 2 (TGase) inhibitor with an IC50 of 7.71 μM for human recombinant TGase 2.

   

(2e,4e)-n-{3-[(4e)-5-hydroxy-4-[(2e,4e)-1-hydroxyhexa-2,4-dien-1-ylidene]-3-oxo-2h-pyrrol-2-yl]propyl}hexa-2,4-dienimidic acid

(2e,4e)-n-{3-[(4e)-5-hydroxy-4-[(2e,4e)-1-hydroxyhexa-2,4-dien-1-ylidene]-3-oxo-2h-pyrrol-2-yl]propyl}hexa-2,4-dienimidic acid

C19H24N2O4 (344.1736)


   

1-(dec-9-en-1-yl)-2-hydroxybutane-1,2,4-tricarboxylic acid

1-(dec-9-en-1-yl)-2-hydroxybutane-1,2,4-tricarboxylic acid

C17H28O7 (344.1835)


   

3-[3-hydroxy-6-isopropyl-2-(methoxycarbonyl)-3-(methoxymethyl)cyclohexyl]-2-(hydroxymethyl)prop-2-enoic acid

3-[3-hydroxy-6-isopropyl-2-(methoxycarbonyl)-3-(methoxymethyl)cyclohexyl]-2-(hydroxymethyl)prop-2-enoic acid

C17H28O7 (344.1835)


   

(2e,4e)-n-(3-{4-[(2e,4e)-hexa-2,4-dienoyl]-5-hydroxy-3-oxo-1,2-dihydropyrrol-2-yl}propyl)hexa-2,4-dienimidic acid

(2e,4e)-n-(3-{4-[(2e,4e)-hexa-2,4-dienoyl]-5-hydroxy-3-oxo-1,2-dihydropyrrol-2-yl}propyl)hexa-2,4-dienimidic acid

C19H24N2O4 (344.1736)


   

5-{6,7-dihydroxy-5-methyl-4-oxo-3,11-dioxabicyclo[6.2.1]undecan-2-yl}pentyl acetate

5-{6,7-dihydroxy-5-methyl-4-oxo-3,11-dioxabicyclo[6.2.1]undecan-2-yl}pentyl acetate

C17H28O7 (344.1835)


   

11-amino-3,4-dimethoxy-13-methyl-9-oxa-13-azapentacyclo[9.4.2.1⁸,¹².0¹,¹².0²,⁷]octadeca-2,4,6-trien-10-one

11-amino-3,4-dimethoxy-13-methyl-9-oxa-13-azapentacyclo[9.4.2.1⁸,¹².0¹,¹².0²,⁷]octadeca-2,4,6-trien-10-one

C19H24N2O4 (344.1736)


   

(1's,3s,4's,6's,7'r,8's,11's)-6'-ethyl-11'-hydroxy-1-methoxy-10'-oxa-5'-azaspiro[indole-3,2'-tricyclo[5.3.1.0⁴,⁸]undecan]-2-one

(1's,3s,4's,6's,7'r,8's,11's)-6'-ethyl-11'-hydroxy-1-methoxy-10'-oxa-5'-azaspiro[indole-3,2'-tricyclo[5.3.1.0⁴,⁸]undecan]-2-one

C19H24N2O4 (344.1736)


   

methyl (4ar,5s,11r,11ar)-11a-hydroxy-5-(hydroxymethyl)-11-methyl-1h,2h,3h,4h,4ah,6h,11h-pyrido[4,3-b]carbazole-5-carboxylate

methyl (4ar,5s,11r,11ar)-11a-hydroxy-5-(hydroxymethyl)-11-methyl-1h,2h,3h,4h,4ah,6h,11h-pyrido[4,3-b]carbazole-5-carboxylate

C19H24N2O4 (344.1736)


   

(1r,8s,11r,12s)-11-amino-3,4-dimethoxy-13-methyl-9-oxa-13-azapentacyclo[9.4.2.1⁸,¹².0¹,¹².0²,⁷]octadeca-2,4,6-trien-10-one

(1r,8s,11r,12s)-11-amino-3,4-dimethoxy-13-methyl-9-oxa-13-azapentacyclo[9.4.2.1⁸,¹².0¹,¹².0²,⁷]octadeca-2,4,6-trien-10-one

C19H24N2O4 (344.1736)


   

methyl 11a-hydroxy-5-(hydroxymethyl)-11-methyl-1h,2h,3h,4h,4ah,6h,11h-pyrido[4,3-b]carbazole-5-carboxylate

methyl 11a-hydroxy-5-(hydroxymethyl)-11-methyl-1h,2h,3h,4h,4ah,6h,11h-pyrido[4,3-b]carbazole-5-carboxylate

C19H24N2O4 (344.1736)


   

2-[(6-amino-1-hydroxy-2-{[hydroxy(5-hydroxy-3,4-dihydro-2h-pyrrol-2-yl)methylidene]amino}hexylidene)amino]-3-hydroxypropanoic acid

2-[(6-amino-1-hydroxy-2-{[hydroxy(5-hydroxy-3,4-dihydro-2h-pyrrol-2-yl)methylidene]amino}hexylidene)amino]-3-hydroxypropanoic acid

C14H24N4O6 (344.1696)


   

6'-ethyl-11'-hydroxy-1-methoxy-10'-oxa-5'-azaspiro[indole-3,2'-tricyclo[5.3.1.0⁴,⁸]undecan]-2-one

6'-ethyl-11'-hydroxy-1-methoxy-10'-oxa-5'-azaspiro[indole-3,2'-tricyclo[5.3.1.0⁴,⁸]undecan]-2-one

C19H24N2O4 (344.1736)


   

n-{3-[(2s,5s)-3,6-dihydroxy-5-[3-(n-hydroxyacetamido)propyl]-2,5-dihydropyrazin-2-yl]propyl}-n-hydroxyacetamide

n-{3-[(2s,5s)-3,6-dihydroxy-5-[3-(n-hydroxyacetamido)propyl]-2,5-dihydropyrazin-2-yl]propyl}-n-hydroxyacetamide

C14H24N4O6 (344.1696)


   

(2s)-2-{[(2r)-6-amino-1-hydroxy-2-({hydroxy[(2s)-5-hydroxy-3,4-dihydro-2h-pyrrol-2-yl]methylidene}amino)hexylidene]amino}-3-hydroxypropanoic acid

(2s)-2-{[(2r)-6-amino-1-hydroxy-2-({hydroxy[(2s)-5-hydroxy-3,4-dihydro-2h-pyrrol-2-yl]methylidene}amino)hexylidene]amino}-3-hydroxypropanoic acid

C14H24N4O6 (344.1696)


   

(2e)-3-[(1s,2s,3s,6r)-3-hydroxy-6-isopropyl-2-(methoxycarbonyl)-3-(methoxymethyl)cyclohexyl]-2-(hydroxymethyl)prop-2-enoic acid

(2e)-3-[(1s,2s,3s,6r)-3-hydroxy-6-isopropyl-2-(methoxycarbonyl)-3-(methoxymethyl)cyclohexyl]-2-(hydroxymethyl)prop-2-enoic acid

C17H28O7 (344.1835)


   

(1'r,3s,4'r,6'r,7's,8'r,11'r)-6'-ethyl-11'-hydroxy-1-methoxy-10'-oxa-5'-azaspiro[indole-3,2'-tricyclo[5.3.1.0⁴,⁸]undecan]-2-one

(1'r,3s,4'r,6'r,7's,8'r,11'r)-6'-ethyl-11'-hydroxy-1-methoxy-10'-oxa-5'-azaspiro[indole-3,2'-tricyclo[5.3.1.0⁴,⁸]undecan]-2-one

C19H24N2O4 (344.1736)


   

(2r,5s)-5-hydroxy-8-methoxy-8-oxooct-6-en-2-yl (4s,7r)-4,7-dihydroxyoct-2-enoate

(2r,5s)-5-hydroxy-8-methoxy-8-oxooct-6-en-2-yl (4s,7r)-4,7-dihydroxyoct-2-enoate

C17H28O7 (344.1835)


   

(2e)-4-[(2s,3s,4s,5r)-3,4-dihydroxy-5-({3-[(2s)-3-hydroxybutan-2-yl]oxiran-2-yl}methyl)oxan-2-yl]-3-methylbut-2-enoic acid

(2e)-4-[(2s,3s,4s,5r)-3,4-dihydroxy-5-({3-[(2s)-3-hydroxybutan-2-yl]oxiran-2-yl}methyl)oxan-2-yl]-3-methylbut-2-enoic acid

C17H28O7 (344.1835)


   

n-(3-{3,6-dihydroxy-5-[3-(n-hydroxyacetamido)propyl]-2,5-dihydropyrazin-2-yl}propyl)-n-hydroxyacetamide

n-(3-{3,6-dihydroxy-5-[3-(n-hydroxyacetamido)propyl]-2,5-dihydropyrazin-2-yl}propyl)-n-hydroxyacetamide

C14H24N4O6 (344.1696)


   

5-[(1s,2r,5r,6s,7r,8r)-6,7-dihydroxy-5-methyl-4-oxo-3,11-dioxabicyclo[6.2.1]undecan-2-yl]pentyl acetate

5-[(1s,2r,5r,6s,7r,8r)-6,7-dihydroxy-5-methyl-4-oxo-3,11-dioxabicyclo[6.2.1]undecan-2-yl]pentyl acetate

C17H28O7 (344.1835)